Antibiotic resistance markers are a necessary tool in many clinical areas

Authors

DOI:

https://doi.org/10.18370/2309-4117.2020.56.49-56

Keywords:

antibiotic resistance, antibiotic suseptibility, resistance markers, extended spectrum β-lactamases, carbapenemases

Abstract

Antibiotic resistance (AR) is one of the leading and still far from solving the problems of mankind. Implementation of strategies for controling AR at different levels is a priority task, since crisis of the possibilities of creating new antibiotics is obvious. Implementation of this strategy in the medical field consists in the rational use of antibacterial agents and hygienic control of the spread of multiresistant strains.

One of the ways to rationalize the use of antimicrobial agents was WHO AWaRe classification, the purpose of which is to expand the use of narrow-spectrum antibiotics and limit the misuse of reserve groups and drugs with growing resistance levels. Implementation of these tasks is impossible without microbiological studies. Laboratory diagnostics of the infectious causes has undergone significant improvement – automation, availability of routine determination of resistance markers. The review presents the main mechanisms of AR development by common pathogens and possibility of their reflection in resistance markers.

An important milestone in 2020 was the Infectious Diseases Society of America (IDSA) clinical guideline for treatment of infectious caused by common multi-resistant gram-negative bacteria. In contrast to previous clinical guidelines, this makes the prescription of antibacterial drugs primarily on information about resistance markers, antibiotic susceptibility, and also on the location of infection. The purpose of the IDSA-2020 clinical guidelines is to assist clinicians in making decisions in treatment of infections caused by extended-spectrum β-lactamase or carbapenemase-producing Enterobacteriaceae bacteria and Pseudomonas feruginosa multi-drug resistant. The review presents the main points of this clinical guideline.

Thus, effective treatment of infections caused by antibiotic-resistant microorganisms is possible due to contemporary microbiological methods according to evidence-based clinical guidelines. Automated microbiological research systems significantly expand the clinical possibilities of effective treatment of infections and epidemiological control of resistant strains.

Author Biographies

T. M. Tutchenko, SI “O.M. Lukyanova IPOG of the NAMS of Ukraine”; SSI “CIMT of the NAS of Ukraine»; “DILA” Medical Laboratory

PhD, senior researcher of the Endocrine Gynecology Department;

Department of Reproductive Health;

Scientific consultant 

O. A. Burka, Bogomolets National Medical University; “DILA” Medical Laboratory

PhD, associate professor at the Obstetrics and Gynaecology Department No. 1;

Scientific consultant 

Y. A. Marfina, RCNE “Chernivtsi Regional Medical Diagnostic Center”

Head of the Regional Center for family planning and human reproduction

T. Y. Tarasiuk, CE “Regional Perinatal Center” of Rivne Regional Council

Obstetrician-gynecologist

T. A. Illiashenko, Kyiv City Center of Reproductive and Perinatal Medicine

Obstetrician-gynecologist

References

  1. Singh, T.A., et al. “Understanding and combating the antibiotic resistance crisis.” Microorganisms for Sustainable Environment and Health (2020): 315.
  2. Ventola, C.L. “The antibiotic resistance crisis: part 1: causes and threats.” Pharmacy and therapeutics 40.4 (2015): 277.
  3. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA. U.S. Department of Health and Human Services, CDC (2019). DOI: 10.15620/cdc:82532
  4. Dyar, O.J., et al. “What is antimicrobial stewardship?” Clinical Microbiology and Infection 23.11 (2017): 793–8.
  5. May, L.S., et al. “Antimicrobial Stewardship in the Emergency Department: characteristics and evidence for effectiveness of interventions.” Clinical Microbiology and Infection (2020).
  6. Eudy, J.L., et al. “Antimicrobial Stewardship Practice in the Ambulatory Setting from a National Cohort.” US: Oxford University Press. Open forum infectious diseases 7.11 (2020).
  7. European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report 2019. Stockholm. ECDC (2020).
  8. Getahun, H., Smith, I., Trivedi, K., et al. “Tackling antimicrobial resistance in the COVID-19 pandemic.” Bull WHO 98 (2020): 442–442A. DOI: 10.2471/BLT.20.268573
  9. Cantón, R., Gijón, D., Ruiz-Garbajosa, P. “Antimicrobial resistance in ICUs: an update in the light of the COVID-19 pandemic.” Current Opinion in Critical Care 26.5 (2020): 433–41.
  10. O’Neill, J. Tackling Drug-resistant Infections Globally: Final Report and Recommendations. The Review on Antimicrobial Resistance. London. HM Government and the Wellcome Trust (2016).
  11. Christaki, E., Marcou, M., Tofarides, A. “Antimicrobial resistance in bacteria: mechanisms, evolution, and persistence.” Journal of molecular evolution 88.1 (2020): 26–40.
  12. Andersson, D.I., et al. “Antibiotic resistance: turning evolutionary principles into clinical reality.” FEMS Microbiology Reviews 44.2 (2020): 171–88.
  13. Salmanov, A., et al. “Prevalence of healthcare-associated infections and antimicrobial resistance in acute care hospitals in Kyiv, Ukraine.” Journal of Hospital Infection 102.4 (2019).
  14. Morency-Potvin, P., Schwartz, D.N., Weinstein, R.A. “Antimicrobial stewardship: how the microbiology laboratory can right the ship.” Clinical microbiology reviews 30.1 (2017): 381–407.
  15. Murray, P.R. “Laboratory automation impact on antimicrobial resistance.” Microbiology Australia 40.2 (2019): 66–8.
  16. Bailey, A.L., Ledeboer, N., Burnham, C.-A.D. “Clinical microbiology is growing up: the total laboratory automation revolution.” Clinical chemistry 65.5 (2019): 634–43.
  17. Martínez, J.L., Coque, T.M., Baquero, F. “What is a resistance gene? Ranking risk in resistomes.” Nature Reviews Microbiology 13.2 (2015): 116–23.
  18. WHO Antibiotic Categorization AWaRe. Available from: [https://aware.essentialmeds.org/groups], last accessed Dec 22, 2020.
  19. Frieri, M., Kumar, K., Boutin, A. “Antibiotic resistance.” Journal of infection and public health 10.4 (2017): 369–78.
  20. Peterson, E., Kaur, P. “Antibiotic resistance mechanisms in bacteria: relationships between resistance determinants of antibiotic producers, environmental bacteria, and clinical pathogens.” Frontiers in microbiology 9 (2018): 2928.
  21. Admassie, M. “Current Review on Molecular and Phenotypic Mechanism of Bacterial Resistance to Antibiotic.” Sci J Clin Med 7 (2018): 13.
  22. Nordmann, P., Poirel, L. “The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide.” Clinical Microbiology and Infection 20.9 (2014): 821–30.
  23. Nordmann, P., Naas, T., Poirel, L. “Global spread of carbapenemase-producing Enterobacteriaceae.” Emerging infectious diseases 17.10 (2011): 1791.
  24. Pitout, J.D.D. “Multiresistant Enterobacteriaceae: new threat of an old problem.” Expert review of anti-infective therapy 6.5 (2008): 657–69.
  25. Bard, J.D., Lee, F. “Why can’t we just use PCR? The role of genotypic versus phenotypic testing for antimicrobial resistance testing.” Clinical Microbiology Newsletter 40.11 (2018): 87–95.
  26. Kollef, M.H. “Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front.” Clinical Infectious Diseases 47 Suppl 1 (2008): S3–S13.
  27. Rhee, C., et al. “Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum empiric antibiotic use.” JAMA Network Open 3.4 (2020).
  28. Tamma, P.D., et al. “Infectious Diseases Society of America Antimicrobial Resistant Treatment Guidance: Gram-Negative Bacterial Infections.” Clinical Infectious Diseases (2020).
  29. Tamma, P.D., et al. “Molecular epidemiology of ceftriaxone-nonsusceptible Enterobacterales isolates in an academic medical center in the United States.” US: Oxford University Press. Open forum infectious diseases 6.8 (2019).
  30. Iovleva, A., Bonomo, R.A. “The ecology of extended-spectrum β-lactamases (ESBLs) in the developed world.” Journal of travel medicine 24 Suppl 1 (2017): S44–S51.
  31. Gupta, K., et al. “International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.” Clinical infectious diseases 52.5 (2011): e103–e120.
  32. Bonkat, G., Pickard, R., Bartoletti, R., et al. EAU Guidelines on Urological Infections. Limited update (2018).
  33. Hooton, T.M., et al. “Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial.” Jama 293.8 (2005): 949–55.
  34. Goodlet, K.J., Benhalima, F.Z., Nailor, M.D. “A systematic review of single-dose aminoglycoside therapy for urinary tract infection: is it time to resurrect an old strategy?” Antimicrobial agents and chemotherapy 63.1 (2019).
  35. Ito, R., et al. “Widespread fosfomycin resistance in Gram-negative bacteria attributable to the chromosomal fosA gene.” MBio 8.4 (2017).
  36. Elliott, Z.S., et al. “The role of fosA in challenges with fosfomycin susceptibility testing of multispecies Klebsiella pneumoniae carbapenemase-producing clinical isolates.” Journal of clinical microbiology 57.10 (2019): e00634–19.
  37. Agwuh, K.N., MacGowan, A. “Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines.” Journal of Antimicrobial Chemotherapy 58.2 (2006): 256–65.
  38. Harris, P.N.A., et al. “Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial.” Jama 320.10 (2018): 984–94.
  39. Chopra, T., et al. “Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.” Antimicrobial agents and chemotherapy 56.7 (2012): 3936–42.
  40. Livermore, D.M., et al. “Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?” Journal of antimicrobial chemotherapy 67.7 (2012): 1569–77.
  41. Zhou, M., et al. “Comparison of five commonly used automated susceptibility testing methods for accuracy in the China Antimicrobial Resistance Surveillance System (CARSS) hospitals.” Infection and drug resistance 11 (2018): 1347.
  42. Burgess, D.S., Hall, R.G. II. “In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.” Diagnostic microbiology and infectious disease 49.1 (2004): 41–6.
  43. European Centre for Disease Prevention and Control. Carbapenem-resistant Enterobacteriaceae, second update – 2019. ECDC. Stockholm (2019).
  44. van Duin, D., et al. “Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes.” Diagnostic microbiology and infectious disease 75.2 (2013): 115–20.
  45. Sorlí, L., et al. “Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical.” Journal of Infection 79.3 (2019): 253–61.
  46. Solomkin, J., et al. “Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial.” JAMA surgery 152.3 (2017): 224–32.
  47. Eckmann, C., et al. “Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies.” Journal of Antimicrobial Chemotherapy 68 Suppl 2 (2013): ii25–ii35.
  48. Babinchak, T., et al. “The efficacy and safety of tigecycline for the treatment of complicated intra- abdominal infections: analysis of pooled clinical trial data.” Clinical Infectious Diseases 41 Suppl 5 (2005): S354–S367.
  49. Falagas, M.E., Karageorgopoulos, D.E., Dimopoulos, G. “Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline.” Current drug metabolism 10.1 (2009): 13–21.
  50. Kadri, S.S., et al. “Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents.” Clinical Infectious Diseases 67.12 (2018): 1803–14.
  51. Moore, N.M., Flaws, M.L. “Antimicrobial resistance mechanisms in Pseudomonas aeruginosa.” Clinical Laboratory Science 24.1 (2011): 47.

Downloads

Published

2020-12-29

How to Cite

Tutchenko, T. M., Burka, O. A., Marfina, Y. A., Tarasiuk, T. Y., & Illiashenko, T. A. (2020). Antibiotic resistance markers are a necessary tool in many clinical areas. REPRODUCTIVE ENDOCRINOLOGY, (56), 49–56. https://doi.org/10.18370/2309-4117.2020.56.49-56

Issue

No. 56 (2020)

Section

Inflammatory diseases

License

Copyright (c) 2020 T. M. Tutchenko, O. A. Burka, Y. A. Marfina, T. Y. Tarasiuk, T. A. Illiashenko

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.